GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MAIA Biotechnology Inc (AMEX:MAIA) » Definitions » ROE % Adjusted to Book Value

MAIA (MAIA Biotechnology) ROE % Adjusted to Book Value : -11.08% (As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is MAIA Biotechnology ROE % Adjusted to Book Value?

MAIA Biotechnology's ROE % for the quarter that ended in Sep. 2024 was -457.81%. MAIA Biotechnology's PB Ratio for the quarter that ended in Sep. 2024 was 41.32. MAIA Biotechnology's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was -11.08%.

MAIA Biotechnology ROE % Adjusted to Book Value Historical Data

The historical data trend for MAIA Biotechnology's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MAIA Biotechnology ROE % Adjusted to Book Value Chart

MAIA Biotechnology Annual Data
Trend Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
- - -39.44 -10.53

MAIA Biotechnology Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -36.85 -37.13 - - -11.08

Competitive Comparison of MAIA Biotechnology's ROE % Adjusted to Book Value

For the Biotechnology subindustry, MAIA Biotechnology's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MAIA Biotechnology's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MAIA Biotechnology's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where MAIA Biotechnology's ROE % Adjusted to Book Value falls into.


MAIA Biotechnology ROE % Adjusted to Book Value Calculation

MAIA Biotechnology's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-440.08% / 41.79
=-10.53%

MAIA Biotechnology's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-457.81% / 41.32
=-11.08%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MAIA Biotechnology ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of MAIA Biotechnology's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

MAIA Biotechnology Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MAIA Biotechnology Inc (AMEX:MAIA) » Definitions » ROE % Adjusted to Book Value
Comparable Companies
LTRN PTN CRIS SIOX SEEL LUMO UBX SLS MTEM CADL OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
444 West Lake Street, Suite 1700, Chicago, IL, USA, 06060
Website
https://www.maiabiotech.com
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.
Executives
Steven M Chaouki director C/O TRANSUNION, 555 WEST ADAMS STREET, CHICAGO IL 60661
Stan Smith director 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Ramiro Guerrero director 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Cristian Luput director 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Ngar Yee Louie director, 10 percent owner 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Vlad Vitoc director, 10 percent owner, officer: Chief Executive Officer 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Joseph F Mcguire officer: Chief Financial Officer 6670 SPRINGLAKE ROAD, KEYSTONE HEIGHTS FL 32656
Jean-manasse Theagene director 500 PLACE D ARMES, SUITE 1800, MONTREAL A8 H2Y 2W2
Sergei Gryaznov officer: Chief Scientific Officer 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Laurentiu Vlad director 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606
Mihail Obrocea officer: Chief Medical Officer 444 WEST LAKE STREET, SUITE 1700, CHICAGO IL 60606